Headlines about ArQule (NASDAQ:ARQL) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ArQule earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6620822145367 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of research firms have recently issued reports on ARQL. B. Riley set a $3.00 target price on ArQule and gave the company a “buy” rating in a report on Thursday, February 8th. ValuEngine upgraded ArQule from a “strong sell” rating to a “sell” rating in a report on Friday, November 17th. Roth Capital began coverage on ArQule in a report on Thursday, February 22nd. They issued a “buy” rating and a $5.00 target price for the company. Zacks Investment Research lowered ArQule from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, Needham & Company LLC upgraded ArQule from a “hold” rating to a “buy” rating in a report on Thursday, December 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. ArQule presently has an average rating of “Hold” and an average price target of $3.17.
ArQule (NASDAQ ARQL) traded down $0.01 during midday trading on Wednesday, hitting $1.82. 117,350 shares of the stock were exchanged, compared to its average volume of 237,511. ArQule has a 1-year low of $0.92 and a 1-year high of $1.98. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.98 and a quick ratio of 4.98. The firm has a market capitalization of $155.06, a P/E ratio of -4.69 and a beta of 1.43.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/03/14/arqule-arql-receives-media-sentiment-score-of-0-09/1925714.html.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.